Oncimmune (ONC) Share Price, News & Analysis

Company Overview

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.

Key Stats

• Today's Range: 12.50 to 12.66
• 50-Day Range: 11.90 to 16.40
• 52-Week Range: 9.35 to 31
• Volume: 25,519 shs
• Average Volume: 267,968 shs
• Market Capitalization: £9.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ONC Stock Analysis - Frequently Asked Questions

How have ONC shares performed this year?

Oncimmune's stock was trading at GBX 14.35 at the start of the year. Since then, ONC stock has decreased by 12.9% and is now trading at GBX 12.50.
View the best growth stocks for 2025 here.

How were Oncimmune's earnings last quarter?

Oncimmune Holdings plc (LON:ONC) issued its earnings results on Tuesday, February, 13th. The company reported ($5.70) earnings per share for the quarter. The business earned $0.08 million during the quarter. Oncimmune had a net margin of 586.08% and a negative trailing twelve-month return on equity of 760.96%.

How do I buy shares of Oncimmune?

Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Oncimmune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncimmune investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), Intel (INTC) and IQE (IQE).

Company Calendar

• Last Earnings: 2/13/2018
• Today: 1/21/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:ONC
• CUSIP: N/A
• CIK: N/A
• Web: oncimmune.com
• Phone: +44-115-8231869
• Fax: N/A
• Employees: 52
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-3,140,000.00
• Net Margins: 586.08%
• Pretax Margin: N/A
• Return on Equity: -760.96%
• Return on Assets: -26.38%

Debt

• Debt-to-Equity Ratio: 806.85
• Current Ratio: 1.13
• Quick Ratio: 0.63

Sales & Book Value

• Annual Sales: £1.21 million
• Price / Sales: 7.66
• Cash Flow: GBX 1.05 per share
• Price / Cash Flow: 11.96
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 74,140,000
• Free Float: N/A
• Market Cap: £9.27 million
• Optionable: Not Optionable
• Beta: 1.19